Novartis’ Sandoz is pushing to wipe out an advantage AbbVie’s Humira enjoys over its biosimilar rival in the EU, securing regulatory acceptance of a filing for a high-concentration formulation of the ...
Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a new autoinjector pen option for Cyltezo, an interchangeable biosimilar to Humira. Cyltezo ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Celltrion USA is offering an 80 mg dose of Yuflyma (adalimumab-aaty), a high-concentration (100mg/ml) and citrate-free formulation of Humira (adalimumab) biosimilar, in the United States. Yuflyma is ...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback